Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. (Q33408380)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23765638%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23765638%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

1 reference

Jorge A. Carrasquillo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23765638%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Dana E Rathkopf

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23765638%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

10

Steven M Larson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23765638%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Michael J. Morris

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23765638%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

5

Susan F Slovin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23765638%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

2

Neeta Pandit-Taskar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23765638%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

9

Howard I Scher

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23765638%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Karen A Autio

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23765638%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Ryan D Stephenson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23765638%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Christina Hong

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23765638%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Glenn Heller

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23765638%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

language of work or name

English

0 references

publication date

13 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23765638%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23765638%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

119

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23765638%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23765638%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

3186-3194

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23765638%20AND%20SRC:MED&resulttype=core&format=json

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

3 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775970

Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775970

Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775970

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775970

Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775970

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775970

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775970

Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.28103

21 January 2018

Identifiers

DOI

10.1002/CNCR.28103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23765638%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23765638%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

PubMed publication ID

23765638

1 reference